ArticleClinical, cosmetic and investigational dermatology2025
Does Bilirubin Have a Causal Relationship With Vitiligo? A Mendelian Randomization Study and Bioinformatics Analysis.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vitiligo is a complex acquired pigmentary disorder whose pathogenesis is closely linked to oxidative stress. Although bilirubin, a potent endogenous antioxidant, has been implicated in various dermatological conditions, its specific role in vitiligo remains poorly defined. This study aims to investigate the causal associations between bilirubin and vitiligo using Mendelian randomization (MR) analysis, complemented by bioinformatics validation to unravel the underlying molecular mechanisms. Methods: Genome-wide association study (GWAS) data pertaining to vitiligo and bilirubin were obtained, followed by the execution of a bidirectional MR analysis. Additionally, we performed a bioinformatics analysis using microarray datasets to identify differentially expressed genes (DEGs) in relation to bilirubin in patients with vitiligo. Pathway enrichment and gene interaction networks were constructed to explore the molecular mechanisms linking bilirubin to vitiligo pathogenesis. Results: Forward MR analysis demonstrated a significant causal relationship between elevated levels of total bilirubin (P=0.038) and direct bilirubin (P=0.013) with reduced risk of vitiligo. In contrast, reverse MR analysis showed no significant causal effect of vitiligo on bilirubin (P>0.05). Bioinformatics analyses identified 136 DEGs in generalized vitiligo, 32 in segmental vitiligo, and 9 in non-segmental vitiligo. Enrichment analysis highlighted significant associations with oxidative stress-related pathways, including PI3K-Akt and JAK-STAT signaling, which are critical in melanocyte survival and immune regulation. Conclusion: This study provides robust evidence supporting a causal relationship between elevated bilirubin and a reduced risk of vitiligo, driven by its antioxidant properties. The identified DEGs and enriched pathways further elucidate the molecular mechanisms of bilirubin in the pathogenesis of vitiligo through oxidative stress, and may provide insights for future therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.